Blood and scan markers to predict benefit from bevacizumab
Part of Cancer clinical trials.
This study looks for blood test markers that may predict who survives at 6 months after starting bevacizumab for glioblastoma that has come back. It does not aim to cure the cancer by itself, but to improve doctors’ ability to choose the most helpful treatment plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 88 years old and have glioblastoma confirmed by pathology
- Your glioblastoma is in the first relapse after surgery, temozolomide, and radiotherapy
- Recent blood tests meet specific targets (white cells, platelets, liver enzymes, and kidney function)
- Your urine protein is under 1 gram in 24 hours (and kidney function is acceptable)
- Your blood pressure is not dangerously high and your heart blood flow problems are stable
- You can take part safely with no recent major bleeding, clot, infection, or certain recent surgeries
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood marker called CD146 can help predict how well patients with a recurrent brain tumor (glioblastoma) respond to a treatment called bevacizumab. The goal is to see if this test can help doctors personalize care.
This trial tests whether adding a special imaging scan (PSMA PET) before and after the drug bevacizumab can help see how the drug affects glioblastoma tumors. It aims to understand tumor changes better, which may help guide future treatments.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.